Overview

Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO

Status:
Unknown status
Trial end date:
2020-06-18
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of sequential therapy with intravitreal dexamethasone implant followed by bevacizumab compared with bevacizumab monotherapy for macular edema (ME) secondary to retinal vein occlusion (RVO).
Phase:
Phase 4
Details
Lead Sponsor:
Yeungnam University College of Medicine
Treatments:
BB 1101
Bevacizumab
Dexamethasone
Dexamethasone acetate